ukatekexo.wordpress.com
Novavax, which began working on a vaccinde for the N1H1 virus earlierthis year, says it produces the first batch of the vaccinew in May. Novavax uses a technologg that greatly speeds the time it takes to make It says it has now completed the genetic engineering and manufacturee of the stock needed to mass producethe virus. As a result, Novavax and the Nationa Institutesof Health’s National Institute of Allergyg and Infectious Diseases have signed an agreement that will let government scientist s evaluate the vaccine.
“The company has committef necessary resources to respond as rapidlu as possible to construct and manufacture VLP vaccine againstr this new N1H1influenza virus,” said Novavax CEO Rahul Singhvi in a statement. Novavax has the capacity to produce largew amounts the vaccine at its manufacturing facilitiedin Rockville. Novavax stock (NASDAQ: NVAX) was up 88 cents to $2.7r per share in afternoon trading. Its stocj was trading as low as 52 cents per share inearlty April.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment